|
|
|
Celularity Inc (NASDAQ: CELU) |
|
|
|
| |
Celularity Inc Outlook |
On November 7 2024 the Celularity Inc provided following guidance
nnCelularity Inc. Raises Full-Year 2024 Revenue Projections Following Strong Sales Performancenn
nnFLORHAM PARK, N.J., November 7, 2024nn – Celularity Inc. (NASDAQ: CELU), a pioneering company in the fields of regenerative and cellular medicine, has announced an upward revision to its revenue forecast for the full fiscal year 2024. The new guidance estimates net sales will reach between nn$54 million and $60 millionnn, an increase from the previously announced range of nn$50 million to $56 millionnn earlier in the year.
This adjustment in guidance is attributable to the robust sales performance recorded through October, particularly in the company's line of advanced biomaterial products. For 2024, Celularity's projections delineate that anticipated net sales will comprise approximately nn$49 million to $54.5 millionnn from advanced biomaterial offerings and an additional nn$5.0 million to $5.5 millionnn generated from biobanking services.
Excitingly, the company is anticipating a remarkable growth trajectory for its advanced biomaterial products, projecting an increase of nn180% to 212%nn compared to the previous year. This significant growth highlights the increasing demand and market acceptance of Celularity's innovative products, further solidifying the company's position in the regenerative medicine sector.
In summary, Celularity Inc.'s enhanced financial outlook for 2024 reflects a strong start to the year and positions the company for accelerated advancement in its sales initiatives across its key product lines.,
|
On July 31 2024 the Celularity Inc provided following guidance
nnCelularity Inc. Financial Update: Strong Growth Anticipated for 2024nn
nnFLORHAM PARK, N.J., July 31, 2024nn — Celularity Inc. (Nasdaq: CELU), a pioneering company in regenerative and cellular medicine focusing on placental-derived allogeneic cell therapies and advanced biomaterial solutions, has released its financial performance metrics for the full year of 2023 and projected sales for the first half of 2024.
The company reported a remarkable nn$22.8 millionnn in combined net sales for 2023, reflecting a substantial increase of nn26.7%nn compared to the 2022 figures. This consistent upward trajectory underscores Celularity's robust growth strategy and its commitment to advancing its innovative product offerings in the regenerative medicine sector.
Looking ahead, Celularity anticipates that its combined net sales for the first half of 2024 will reach an impressive nn$26.9 millionnn. This projection marks an astounding growth rate of nn290%nn when compared to the same period last year. Such an exponential increase is indicative of the rising demand for Celularity's advanced biomaterials and biobanking services.
In defining its net sales, Celularity specifies that the figures encompass revenue generated directly from customers and distributors relating to its advanced biomaterial products and biobanking services. It's important to note that these figures do not account for revenues derived from other channels, including research collaboration agreements or associated fees.
As Celularity continues to push the boundaries of regenerative medicine, stakeholders and industry observers are keenly watching its progression and the impact of its cutting-edge therapies on healthcare. The company's strategic direction and financial performance signal a promising future in its market endeavors.
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.
